Identification of Drug-Like Inhibitors of Insulin-Regulated Aminopeptidase Through Small-Molecule Screening

Assay and Drug Development Technologies

Volumn 14, Issue 3, 2016, Pages 180-193

  Engen, Karin ^a   Rosenström, Ulrika ^a   Axelsson, Hanna ^b   Konda, Vivek ^a   Dahllund, Leif ^c   Otrocka, Magdalena ^b   Sigmundsson, Kristmundur ^b,e   Nikolaou, Alexandros ^d,f   Vauquelin, Georges ^d   Hallberg, Mathias ^a   Jenmalm Jensen, Annika ^b   Lundbäck, Thomas ^b   Larhed, Mats ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SCIENCE FOR LIFE LABORATORY   (Sweden)

^d VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^e DUKE NUS MEDICAL SCHOOL   (Singapore)

^f CENTRE FOR GENOMIC REGULATION CRG   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROXINE; CLIOQUINOL; DETERGENT; ENZYME INHIBITOR; INSULIN REGULATED AMINOPEPTIDASE INHIBITOR; MERBROMIN; REDUCING AGENT; TOPOTECAN; UNCLASSIFIED DRUG; VATALANIB; VERTEPORFIN; CYSTYL AMINOPEPTIDASE; LEUCYL-CYSTINYL AMINOPEPTIDASE; MOLECULAR LIBRARY; PROTEINASE INHIBITOR;

ANIMAL CELL; ARTICLE; CHO CELL LINE; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG SCREENING; ENZYMATIC ASSAY; EXPERIMENT; FEMALE; FLUORESCENCE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MEMBRANE; NONHUMAN; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL CULTURE; CHEMISTRY; CRICETULUS; DOSE RESPONSE; HEK293 CELL LINE; MOLECULAR LIBRARY; PHARMACOLOGY; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELLS, CULTURED; CHO CELLS; CRICETULUS; CYSTINYL AMINOPEPTIDASE; DOSE-RESPONSE RELATIONSHIP, DRUG; HEK293 CELLS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEASE INHIBITORS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84964825360     PISSN: 1540658X     EISSN: 15578127     Source Type: Journal    
DOI: 10.1089/adt.2016.708     Document Type: Article

References (53)

1. Prince M, Wimo A, Guerchet M, et al.: World Alzheimer Report 2015, The Global Impact of Dementia, an Analysis of Prevalence, Incidence, Cost and Trends. Alzheimer's Disease International, London, United Kingdom, 2015.
2. Braszko J, Kupryszewski G, Witczuk B, Wiśniewski K: Angiotensin II-(3-8)-hexapeptide affects motor activity, performance of passive avoidance and a conditioned avoidance response in rats. Neuroscience 1988;27:777-783.
3. Wright JW, Miller-Wing AV, Shaffer MJ, et al.: Angiotensin II(3-8) (ANG IV) hippocampal binding: Potential role in the facilitation of memory. Brain Res Bull 1993;32:497-502.
4. Wright JW, Clemens JA, Panetta JA, et al.: Effects of LY231617 and angiotensin IV on ischemia-induced deficits in circular water maze and passive avoidance performance in rats. Brain Res 1996;717:1-11.
5. Wright JW, Stubley L, Pederson ES, et al.: Contributions of the brain angiotensin IV-AT4 receptor subtype system to spatial learning. J Neurosci 1999;19:3952-3961.
6. Lee J, Albiston AL, Allen AM, et al.: Effect of I.C.V. injection of AT4 receptor ligands, NLE1-angiotensin IV and LVV-hemorphin 7, on spatial learning in rats. Neuroscience 2004;124:341-349.
7. Braszko JJ, Wielgat P, Walesiuk A: Effect of D(3) dopamine receptors blockade on the cognitive effects of angiotensin IV in rats. Neuropeptides 2008;42:301-309.
8. De Bundel D, Smolders I, Yang R, et al.: Angiotensin IV and LVV-haemorphin 7 enhance spatial working memory in rats: Effects on hippocampal glucose levels and blood flow. Neurobiol Learn Mem 2009;92:19-26.
9. Miller-Wing AV, Hanesworth JM, Sardinia MF, et al.: Central angiotensin IV binding sites: Distribution and specificity in guinea pig brain. J Pharmacol Exp Ther 1993;266:1718-1726.
10. Roberts KA, Krebs LT, Kramár EA, et al.: Autoradiographic identification of brain angiotensin IV binding sites and differential c-Fos expression following intracerebroventricular injection of angiotensin II and IV in rats. Brain Res 1995;682:13-21.
11. Moeller I, Chai SY, Oldfield BJ, et al.: Localization of angiotensin IV binding sites to motor and sensory neurons in the sheep spinal cord and hindbrain. Brain Res 1995;701:301-306.
12. Moeller I, Paxinos G, Mendelsohn FA, et al.: Distribution of AT4 receptors in the Macaca fascicularis brain. Brain Res 1996;712:307-324.
13. Albiston AL, McDowall SG, Matsacos D, et al.: Evidence that the angiotensin IV (AT(4)) receptor is the enzyme insulin-regulated aminopeptidase. J Biol Chem 2001;276:48623-48626.
14. Matsumoto H, Rogi T, Yamashiro K, et al.: Characterization of a recombinant soluble form of human placental leucine aminopeptidase/oxytocinase expressed in Chinese hamster ovary cells. Eur J Biochem 2000;267:46-52.
15. Wallis MG, Lankford MF, Keller SR: Vasopressin is a physiological substrate for the insulin-regulated aminopeptidase IRAP. Am J Physiol Endocrinol Metab 2007;293:E1092-E1102.
16. Saveanu L, Van Endert P: The role of insulin-regulated aminopeptidase in MHC class I antigen presentation. Front Immunol 2012;3:1-13.
17. Waters SB, D'Auria M, Martin SS, et al.: The amino terminus of insulin-responsive aminopeptidase causes Glut4 translocation in 3T3-L1 adipocytes. J Biol Chem 1997;272:23323-23327.
18. Lukaszuk A, Demaegdt H, Feytens D, et al.: The replacement of His(4) in angiotensin IV by conformationally constrained residues provides highly potent and selective analogues. J Med Chem 2009;52:5612-5618.
19. Lukaszuk A, Demaegdt H, Szemenyei E, et al.: Beta-homo-amino acid scan of angiotensin IV. J Med Chem 2008;51:2291-2296.
20. Nikolaou A, Eynde I, Van Den Tourwé D, et al.: [3H]IVDE77, a novel radioligand with high affinity and selectivity for the insulin-regulated aminopeptidase. Eur J Pharmacol 2013;702:93-102.
21. Axén A, Lindeberg G, Demaegdt H, et al.: Cyclic insulin-regulated aminopeptidase (IRAP)/AT4 receptor ligands. J Pept Sci 2006;12:705-713.
22. Axén A, Andersson H, Lindeberg G, et al.: Small potent ligands to the insulin-regulated aminopeptidase (IRAP)/AT(4) receptor. J Pept Sci 2007;13:434-444.
23. Andersson H, Demaegdt H, Vauquelin G, et al.: Ligands to the (IRAP)/AT4 receptor encompassing a 4-hydroxydiphenylmethane scaffold replacing Tyr2. Bioorganic Med Chem 2008;16:6924-6935.
24. Andersson H, Demaegdt H, Vauquelin G, et al.: Disulfide cyclized tripeptide analogues of angiotensin IV as potent and selective inhibitors of insulin-regulated aminopeptidase (IRAP). J Med Chem 2010;53:8059-8071.
25. Andersson H, Demaegdt H, Johnsson A, et al.: Potent macrocyclic inhibitors of insulin-regulated aminopeptidase (IRAP) by olefin ring-closing metathesis. J Med Chem 2011;54:3779-3792.
26. Diwakarla S, Nylander E, Gronbladh A, et al.: Binding to and inhibition of insulin-regulated aminopeptidase (IRAP) by macrocyclic disulfides enhances spine density. Mol Pharmacol 2016;89:413-424.
27. Zervoudi E, Saridakis E, Birtley JR, et al.: Rationally designed inhibitor targeting antigen-trimming aminopeptidases enhances antigen presentation and cytotoxic T-cell responses. Proc Natl Acad Sci USA 2013;110:19890-19895.
28. Papakyriakou A, Zervoudi E, Theodorakis E, A, et al.: Novel selective inhibitors of aminopeptidases that generate antigenic peptides. Bioorganic Med Chem Lett 2013;23:4832-4836.
29. Papakyriakou A, Zervoudi E, Tsoukalidou S, et al.: 3, 4-diaminobenzoic acid derivatives as inhibitors of the oxytocinase subfamily of M1 aminopeptidases with immune-regulating properties. J Med Chem 2015;58:1524-1543.
30. Albiston AL, Morton CJ, Ng HL, et al.: Identification and characterization of a new cognitive enhancer based on inhibition of insulin-regulated aminopeptidase. FASEB J 2008;22:4209-4217.
31. Mountford S, J, Albiston A, L, Charman W, N, et al.: Synthesis, structure-activity relationships and brain uptake of a novel series of benzopyran inhibitors of insulin-regulated aminopeptidase. J Med Chem 2014;57:1368-1377.
32. Demaegdt H, Vanderheyden P, De Backer J-P, et al.: Endogenous cystinyl aminopeptidase in Chinese hamster ovary cells: Characterization by [125I]Ang IV binding and catalytic activity. Biochem Pharmacol 2004;68:885-892.
33. Demaegdt H, Lukaszuk A, De Buyser E, et al.: Selective labeling of IRAP by the tritiated AT4 receptor ligand [3H]Angiotensin IV and its stable analog [3H]AL-11. Mol Cell Endocrinol 2009;311:77-86.
34. Zhang J-H, Chung TD, Oldenburg KR: A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen 1999;4:67-73.
35. Engen K, Sävmarker J, Rosenström U, et al.: Microwave heated flow synthesis of spiro-oxindole dihydroquinazolinone based IRAP inhibitors. Org Process Res Dev 2014;18:1582-1588.
36. Borhade SR, Rosenström U, Sävmarker J, et al.: Inhibition of insulin-regulated aminopeptidase (IRAP) by arylsulfonamides. Chemistry Open 2014;3:256-263.
37. Laustsen PG, Vang S, Kristensen T: Mutational analysis of the active site of human insulin-regulated aminopeptidase. Eur J Biochem 2001;268:98-104.
38. Lew RA, Mustafa T, Ye S, et al.: Angiotensin AT4 ligands are potent, competitive inhibitors of insulin regulated aminopeptidase (IRAP). J Neurochem 2004;86:344-350.
39. Demaegdt H, Lenaerts P, J, Swales J, et al.: Angiotensin AT4 receptor ligand interaction with cystinyl aminopeptidase and aminopeptidase N: [125I]Angiotensin IV only binds to the cystinyl aminopeptidase apo-enzyme. Eur J Pharmacol 2006;546:19-27.
40. Lundholt BK, Scudder KM, Pagliaro L: A simple technique for reducing edge effect in cell-based assays. J Biomol Screen 2003;8:566-570.
41. Wu G, Yuan Y, Hodge CN: Determining appropriate substrate conversion for enzymatic assays in high-throughput screening. J Biomol Screen 2003;8:694-700.
42. Tholander F: Improved inhibitor screening experiments by comparative analysis of simulated enzyme progress curves. PLoS One 2012;7:e46764.
43. Baell JB, Holloway GA: New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J Med Chem 2010;53:2719-2740.
44. Baell JB: Observations on screening-based research and some concerning trends in the literature. Future Med Chem 2010;2:1529-1546.
45. Baell J, Walters MA: Chemistry: Chemical con artists foil drug discovery. Nature 2014;513:481-483.
46. Wang Y, Xiao J, Suzek T, O, et al.: PubChem's BioAssay database. Nucleic Acids Res 2012;40:D400-D412.
47. Bento AP, Gaulton A, Hersey A, et al.: The ChEMBL bioactivity database: An update. Nucleic Acids Res 2014;42:D1083-D1090.
48. Ward TJ, Crossley R, Slater MJ: Biofocus Discovery Ltd.: Imidazopyridine derivatives as BSR-3 antagonists. WO2005080390, February 16, 2005.
49. Copeland RA: Lead optimization and structure-activity relationships for reversible inhibitors. In: Evaluation of Enzyme Inhibitors in Drug Discovery: A Guide for Medicinal Chemists and Pharmacologists. pp. 169-201. John Wiley & Sons, Inc., Hoboken, New Jersey.
50. Thorne N, Auld DS, Inglese J: Apparent activity in high-throughput screening: Origins of compound-dependent assay interference. Curr Opin Chem Biol 2010;14:315-324.
51. Acker MG, Auld DS: Considerations for the design and reporting of enzyme assays in high-throughput screening applications. Perspect Sci 2014;1:56-73.
52. Irwin JJ, Duan D, Torosyan H, et al.: An aggregation advisor for ligand discovery. J Med Chem 2015;58:7076-7087.
53. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. J Mol Biol 1990;215:403-410.